The 36-month beta value for ATRA is at 0.45. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 3 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ATRA is 3.97M, and currently, shorts hold a 16.10% of that float. The average trading volume for ATRA on November 05, 2024 was 126.33K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ATRA) stock’s latest price update
The stock price of Atara Biotherapeutics Inc (NASDAQ: ATRA) has jumped by 19.77 compared to previous close of 9.71. Despite this, the company has seen a gain of 31.71% in its stock price over the last five trading days. zacks.com reported 2024-10-15 that Atara Biotherapeutics (ATRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company’s earnings prospects. This might drive the stock higher in the near term.
ATRA’s Market Performance
Atara Biotherapeutics Inc (ATRA) has seen a 31.71% rise in stock performance for the week, with a 51.24% gain in the past month and a 40.63% surge in the past quarter. The volatility ratio for the week is 12.22%, and the volatility levels for the past 30 days are at 7.81% for ATRA. The simple moving average for the past 20 days is 31.15% for ATRA’s stock, with a -10.64% simple moving average for the past 200 days.
Analysts’ Opinion of ATRA
Many brokerage firms have already submitted their reports for ATRA stocks, with Mizuho repeating the rating for ATRA by listing it as a “Neutral.” The predicted price for ATRA in the upcoming period, according to Mizuho is $1 based on the research report published on November 09, 2023 of the previous year 2023.
ATRA Trading at 39.61% from the 50-Day Moving Average
After a stumble in the market that brought ATRA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -70.56% of loss for the given period.
Volatility was left at 7.81%, however, over the last 30 days, the volatility rate increased by 12.22%, as shares surge +50.65% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +62.89% upper at present.
During the last 5 trading sessions, ATRA rose by +31.71%, which changed the moving average for the period of 200-days by -26.74% in comparison to the 20-day moving average, which settled at $8.87. In addition, Atara Biotherapeutics Inc saw -9.28% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ATRA starting from Touchon Pascal, who sale 3,038 shares at the price of $6.63 back on Aug 16 ’24. After this action, Touchon Pascal now owns 70,127 shares of Atara Biotherapeutics Inc, valued at $20,139 using the latest closing price.
Nguyen AnhCo, the EVP, Chief Sci. & Tech Officer of Atara Biotherapeutics Inc, sale 1,821 shares at $6.63 during a trade that took place back on Aug 16 ’24, which means that Nguyen AnhCo is holding 34,118 shares at $12,072 based on the most recent closing price.
Stock Fundamentals for ATRA
Current profitability levels for the company are sitting at:
- -2.68 for the present operating margin
- 0.8 for the gross margin
The net margin for Atara Biotherapeutics Inc stands at -29.02. The total capital return value is set at 5.4. Equity return is now at value -2014.86, with -99.55 for asset returns.
Based on Atara Biotherapeutics Inc (ATRA), the company’s capital structure generated -0.86 points at debt to capital in total, while cash flow to debt ratio is standing at -2.78. The debt to equity ratio resting at -0.46. The interest coverage ratio of the stock is -33.55.
Currently, EBITDA for the company is -264.45 million with net debt to EBITDA at -0.36. When we switch over and look at the enterprise to sales, we see a ratio of 1.99. The receivables turnover for the company is 24.74for trailing twelve months and the total asset turnover is 0.53. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.42.
Conclusion
In conclusion, Atara Biotherapeutics Inc (ATRA) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
